03 June 2025 : Database Analysis
Benefits of Sodium-Glucose Cotransporter-2 Inhibitors with Renin-Angiotensin System Blockers in Type-2 Diabetes: A Cohort Analysis
Ming-Hsien Tsai ADE 1, Mingchih Chen
CD 2, Yen-Chun Huang C 3, Wei-Shan Chang C 4, Kai-Yuan Hsiao C 4, Hung-Hsiang Liou A 5, Yu-Wei Fang AEF 6*
DOI: 10.12659/MSM.947153
Med Sci Monit 2025; 31:e947153
Figure 1 Schema of patient enrollment in the study. T2DM – type 2 diabetes mellitus; RASB – renin-angiotensin system blockers; HF – heart failure; ESRD – end-stage renal disease; AKI – acute kidney injury; CAD – coronary artery disease; ACS – acute coronary syndrome; DPP4i – dipeptidyl peptidase 4 inhibitors; SGLT2i – sodium-glucose cotransporter 2 inhibitors; CCI – Charlson comorbidity index.